Evidence map›Paper›PMID 35849613›Full record

ReviewPloS one2022

Indirect COVID-19 health effects and potential mitigating interventions: Cost-effectiveness framework.

Sigal Maya, James G Kahn, Tracy K Lin, Laurie M Jacobs, Laura A Schmidt, William B Burrough, Rezvaneh Ghasemzadeh, Leyla Mousli, Matthew Allan, Maya Donovan and 5 more

Abstract readReview
In one paragraph

Review in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  3. Incentive Spirometer in COVID-19: A Systematic Review.Journal of clinical medicine · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sigal MayaPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.ORCID 0000-0002-3282-8297
James G KahnPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.
Tracy K LinInstitute for Health and Aging, University of California San Francisco, San Francisco, CA, United States of America.ORCID 0000-0002-6528-4564
Laurie M JacobsPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.
Laura A SchmidtPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.
William B BurroughUniversity of California San Francisco Benioff Children's Hospital Oakland, Oakland, CA, United States of America.
Rezvaneh GhasemzadehUniversity of California San Francisco Benioff Children's Hospital Oakland, Oakland, CA, United States of America.
Leyla MousliPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.
Matthew AllanPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.
Maya DonovanPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.
Erin BarkerPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.ORCID 0000-0002-8485-2723
Hacsi HorvathPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.ORCID 0000-0001-7569-3524
Joanne SpetzPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.ORCID 0000-0003-3112-5511
Claire D BrindisPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.
Mohsen MalekinejadPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, United States of America.

Funding

Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Increasing access to medication-assisted treatment: Interactions between federal and state workforce policiesR01DA047379 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SPETZ, JOANNE E. · 2020 to 2022
$1.1M
NCATS NIH HHS UL1 TR001872NIDA NIH HHS R01 DA047379
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic led to important indirect health and social harms in addition to deaths and morbidity due to SARS-CoV-2 infection. These indirect impacts, such as increased depression and substance abuse, can have persistent effects over the life course. Estimated health and cost outcomes of such conditions and mitigation strategies may guide public health responses.

methodsWe developed a cost-effectiveness framework to evaluate societal costs and quality-adjusted life years (QALYs) lost due to six health-related indirect effects of COVID-19 in California. Short- and long-term outcomes were evaluated for the adult population. We identified one evidence-based mitigation strategy for each condition and estimated QALYs gained, intervention costs, and savings from averted health-related harms. Model data were derived from literature review, public data, and expert opinion.

resultsPandemic-associated increases in prevalence across these six conditions were estimated to lead to over 192,000 QALYs lost and to approach $7 billion in societal costs per million population over the life course of adults. The greatest costs and QALYs lost per million adults were due to adult depression. All mitigation strategies assessed saved both QALYs and costs, with five strategies achieving savings within one year. The greatest net savings over 10 years would be achieved by addressing depression ($242 million) and excessive alcohol use ($107 million). DISCUSSION: The COVID-19 pandemic is leading to significant human suffering and societal costs due to its indirect effects. Policymakers have an opportunity to reduce societal costs and health harms by implementing mitigation strategies.

Indexed as

COVID-19AdultCost-Benefit AnalysisHumansPandemicsQuality-Adjusted Life YearsSARS-CoV-2

Identifiers

PMID35849613
PMCPMC9292069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.